ClinicalTrials.gg
CompletedNCT06923956Updated Apr 11, 2025

Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

A Phase 1 interventional study of Bempedoic Acid Film Coated Tablet and Nilemdo® (Bempedoic Acid) Film-coated tablets in Hypercholesterolaemia, Mixed Dyslipidaemia and Cardiovascular Diseases, sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
21st of 21
14 · median 126
Started
2024
with 1 other
Phase 1
3 of 21
none open now
Registered
18th of 21
by date
Lead sponsor
2 of 21
Humanis Saglık Anonim Sirketi

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 21st largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 18th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.

03

Conditions studied

  • Hypercholesterolaemia
  • Mixed Dyslipidaemia
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 55 years old, both inclusive.
  • Gender: Male and/or non-pregnant, non-lactating female.
  • Female of must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to first dosing day. They must be using an acceptable form of .

For female of child-bearing potential, acceptable forms of contraception include the following:

  • Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
  • Barrier methods containing or used in conjunction with a spermicidal agent, or
  • Surgical sterilization or
  • Practicing sexual abstinence throughout the course of the study.
  • Female will not be considered of child-bearing potential if one of the following is reported and documented on the medical history:
  • with spontaneous amenorrhea for at least one year, or
  • Spontaneous amenorrhea for more than 6 months and less than one year with Serum Follicular Stimulating Hormone (FSH) level > 40 mIU/mL, or
  • Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
  • Total hysterectomy and an absence of bleeding for at least 3 months.
  • : 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
  • Non-smokers and non-tobacco user (i.e. having no past history of smoking and tobacco consuming for at least one year prior to study).
  • Able to communicate effectively with study personnel.
  • Willing to provide written to participate in the study.
  • All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include:

Exclusion criteria

Exclusion Criteria:

  • History of allergic responses to Bempedoic acid or other related drugs, or any of its formulation ingredients.
  • Have significant diseases or abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, recording, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
  • Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
  • History or presence of bronchial asthma.
  • Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.
  • Use of any depot injection or implant of any drug within 3 months prior to the first dose of study medication.
  • Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see https://drug-interactions.medicine.iu.edu/MainTable.aspx).
  • History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • A positive hepatitis screen (includes subtypes B \& C).
  • A positive test result for antibody.
  • Volunteer who have received a known drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
  • Volunteer who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
  • History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.
  • Intolerance to venipuncture
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
  • Institutionalized volunteer.
  • Use of any prescribed medications (including simvastatin and pravastatin) within 14 days prior to the first dose of study medication.
  • Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
  • Use of grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
  • Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeinecontaining sodas, colas, etc.), recreational drugs, alcohol or other alcohol containing products within 48 hours prior to the first dose of study medication.
  • Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
  • Volunteer having serum uric acid higher than the during screening.
  • , ALT values are 1.1 times higher than the upper limit of normal range during screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Bempedoic Acid Film Coated Tablet

    Bempedoic Acid 180 mg Film Coated Tablet

    Drug: Bempedoic Acid Film Coated Tablet

  • Active comparator
    Nilemdo® (Bempedoic Acid) Film-coated tablets

    Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets

    Drug: Nilemdo® (Bempedoic Acid) Film-coated tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum measured plasma concentration over the time span specified (Cmax)

    The 90% confidence interval of the relative mean (geometric least square mean) of the test to reference product for Ln-transformed Pharmacokinetic parameters Cmax was to be within 80.00% to 125.00% for Bempedoic Acid to establish bioequivalence.

    Time frame: 72.00 hours

  2. The area under the plasma concentration versus time curve was calculated using the linear trapezoidal linear interpolation rule from the zero time point to the last quantifiable concentration (AUCt)

    The 90% confidence interval of the relative mean (geometric least square mean) of the test to reference product for Ln-transformed Pharmacokinetic parameters AUCt was to be within 80.00% to 125.00% for Bempedoic Acid to establish bioequivalence.

    Time frame: 72.00 hours

Secondary outcomes

  1. The area under the plasma concentration versus time curve from zero to infinity was calculated by adding Ct/Kel to AUCt, where Ct was the last quantifiable concentration and Kel was the elimination rate constant (AUCi)

    Descriptive statistics

    Time frame: 72.00 hours

  2. Time of the maximum measured plasma concentration. If the maximum plasma concentration occurs at more than one time point, the first was chosen as Tmax (Tmax)

    Descriptive statistics

    Time frame: 72.00 hours

  3. The terminal elimination rate constant was obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the natural log of the concentration versus time plot for these points (Kel)

    Descriptive statistics

    Time frame: 72.00 hours

  4. The half-life was calculated by the equation tHalf = 0.693/ Kel (tHalf)

    Descriptive statistics

    Time frame: 72.00 hours

07

Study locations

1 site
  • Cliantha Research Limited
    Noida, Uttar Pradesh 201301, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Dec 2024, 0 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 11, 2025
StartActual
Dec 4, 2024
Primary completionActual
Dec 18, 2024
CompletionActual
Feb 8, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06923956
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Dec 4, 2024
Primary completion
Dec 18, 2024
Completion
Feb 8, 2025
Last update
Apr 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion